(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
19 May 2005 (19.05.2005)

PCT

(10) International Publication Number
WO 2005/044231 A1

(51) International Patent Classification[7]: A61K 9/10, 31/56, 31/7036

(21) International Application Number: PCT/US2004/035562

(22) International Filing Date: 27 October 2004 (27.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/698,322 31 October 2003 (31.10.2003) US

(71) Applicant *(for all designated States except US)*: **BAUSCH & LOMB INCORPORATED** [US/US]; One Bausch & Lomb Place, Rochester, NY 14604 (US).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **KRISHNAMOORTHY, Ramesh** [US/US]; 403 Sherwood Forest Place, Cary, NC 27519 (US).

(74) Agents: **SMITH, Glenn, D.** et al.; Bausch & Lomb Incorporated, One Bausch & Lomb Place, Rochester, NY 14604 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SUSPENSION OF LOTEPREDNOL ETABONATE AND TOBRAMYCIN FOR TOPICAL OPHTHALMIC USE

(57) Abstract: This invention relates to formulations for topical use comprising antibiotics in combination with anti-inflammatory steroids for treating ophthalmic infections and attendant inflammation. More specifically, this invention relates to pharmaceutical ophthalmic formulations comprising a pH stabilizing amount of tobramycin and the soft steroid loteprednol etabonate.

WO 2005/044231 A1

SUSPENSION OF LOTEPREDNOL ETABONATE AND TOBRAMYCIN FOR TOPICAL OPHTHALMIC USE

FIELD OF THE INVENTION

This invention relates to formulations for topical use comprising antibiotics in combination with anti-inflammatory steroids for treating ophthalmic infections and attendant inflammation. More specifically, this invention relates to pharmaceutical ophthalmic formulations comprising a pH stabilizing amount of tobramycin and the soft steroid loteprednol etabonate.

BACKGROUND OF THE INVENTION

Topical steroids such as corticosteroids are commonly used for anti-inflammatory therapy of the eye, especially for treating inflammatory conditions of the palpebral or bulbar conjunctiva, cornea and anterior segment of the globe. Common therapeutic applications for steroids include allergic-conjunctivitis, acne rosacea, superficial punctate keratitis and iritis cyclitis. Steroids also are used to ameliorate inflammation associated with corneal injury due to chemical or thermal burns, or penetration of foreign bodies. Such conditions may result from surgery, injury, allergy or infection to the eye and can cause severe discomfort.

Despite their therapeutic advantages, topical ocular use of corticosteroids is associated with a number of complications, including posterior subcapsular cataract formation, elevation of intraocular pressure, secondary ocular infection, retardation of corneal wound healing, uveitis, mydriasis, transient ocular discomfort and ptosis. Numerous systemic complications also may arise from the topical ocular application of corticosteroids. These complications include adrenal insufficiency, Cushing's syndrome,

peptic ulceration, osteoporosis, hypertension, muscle weakness or atrophy, inhibition of growth, diabetes, activation of infection, mood changes and delayed wound healing.

Topical steroids for treating ocular inflammations can be based on soft drugs. Soft drugs, as is known in the art, are designed to provide maximal therapeutic effect and minimal side effects. By one approach, synthesis of a "soft drug" can be achieved by structurally modifying a known inactive metabolite of a known active drug to produce an active metabolite that undergoes a predictable one-step transformation in-vivo back to the parent, inactive metabolite (see, U.S. Pat. Nos. 6,610,675, 4,996,335 and 4,710,495 for soft steroids). "Soft drugs" therefore are biologically active chemical components characterized by predictable in vivo metabolism to non-toxic derivatives after they provide their therapeutic effect. Formulations of cortico steroids suitable for ophthalmic use are known. For example, US patents 4,710,495, 4,996,335, 5,540,930, 5,747,061, 5,916,550, 6,368,616 and 6,610,675, the contents of each of which is incorporated by reference herein, describe soft steroids and formulations containing soft steroids.

Antibiotic agents for use in treating ophthalmic infections are also known. For example penicillins, cephalosporins and aminoglycosides such as amikacin, gentamicin and tobramycin are known to be useful in treating infections of the eye. Tobramycin is commercially marketed and well recognized as an effective antibiotic. This particular anti-infective is recognized as active against the common bacterial eye pathogens: Staphylococci, including *S. aureus* and *S. epidermidis*, including penicillin resistant strains, Streptococci, including *S. pneumoniae*, *Pseudomonas aeruginosa*, *Escherichia coli*, *Klebsiella pneumoniae*, *Enterobacter aerogenes*, *Proteus mirabilis*, *Morganella morganii*, *Haemophilus influenzae*, *H. aegyptius*, *Acinetobacter calcoaceticus* and some *Neissaria* species. Tobramycin's antimicrobial activity is provided by its ability to bind

with the 30S ribosomal subunit and alter protein synthesis, thus leading to the death of the microbial organism.

It has previously been suggested that the steroid loteprednol etabonate (LE) can be combined with antibiotics such as tobramycin. However, there has been no suggestion of the amount of tobramycin to be used in combination with LE to provide a desired therapeutic effect of both active agents. There has also been no detailed description of a combined formulation having satisfactory properties for storage and use of the combination of tobramycin and LE.

It is known that formulations containing steroids can experience stability problems. Such stability problems include clumping and other undesirable changes upon storage. U.S. Patent No. 5,916,550 describes the use of C_2-C_7 aliphatic amino acids to control pH depression of aqueous suspensions of LE on prolonged storage. Therefore, the need to provide pharmaceutical formulations of steroids that are stable upon storage is well recognized. One of the factors used to evaluate stability of pharmaceutical formulations is pH. When there is a dramatic change in the pH of a pharmaceutical formulation over time, the ability of the formulation to be effectively stored and retain its pharmaceutical activity after storage becomes questionable. It is known to add buffers to certain pharmaceutical formulations in an effort to maintain the stability of the formulation during storage. Examples of buffers include borate buffers, phosphate buffers, etc. Although these buffers are useful in stabilizing pH, they do not demonstrate pharmaceutical activity. Therefore, it would be desirable to use a single material to provide pH stabilizing activity and desired anti-infection activity to pharmaceutical ophthalmic formulations containing the soft steroid loteprednol etabonate.

SUMMARY OF THE INVENTION

It has surprisingly been discovered that the aminoglycoside tobramycin, when present in a pH stabilizing amount, helps to stabilize loteprednol etabonate containing formulations over time to provide better storage characteristics.

This invention provides novel compositions of matter containing a combination of water-soluble and water-insoluble drugs suitable for therapeutic use. The invention provides pH stable aqueous suspensions of water-insoluble drugs that remain in such a state even after extended periods of storage.

More particularly, the invention is directed to aqueous suspensions of soft steroids such as loteprednol etabonate in combination with aminoglycosides such as tobramycin suitable for therapeutic use in the eye, ear, or nose. The aqueous suspensions of LE and tobramycin are surprisingly pH stable and can remain in a pH stable state for extended periods of storage.

Formulations comprising the broad spectrum aminoglycoside antibiotic tobramycin in combination with the predictably metabolized steroid loteprednol etabonate provide pharmaceutical ophthalmic formulations that not only allow for the simultaneous treatment of inflammation and infection in a patient in need of treatment thereof, but also results in a pharmaceutical ophthalmic formulation having increased stability, as measured by decreased change in pH as compared to similar formulations that do not contain tobramycin.

Further provided herein is a topical eye drop medication indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists. The medication comprises a loteprednol etabonate/tobramycin ophthalmic suspension,

0.5%/0.3%. The use of this medication is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.

Also provided herein is a therapeutically effective composition comprising a soft steroid such as loteprednol etabonate in an amount effective to provide a therapeutic benefit to a patient to whom the composition is administered and a pH stabilizing amount of tobramycin, wherein the tobramycin is present in an amount effective to stabilize the pH of the composition relative to the pH of a similar formulation without the tobramycin.

Also provided herein is a method of treating a patient having inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or risk of bacterial ocular infection exists, the method comprising topically applying to a patient in need of treatment thereof a therapeutic amount of a pharmaceutical composition comprising the broad spectrum aminoglycoside antibiotic tobramycin in combination with the predictably metabolized steroid loteprednol etabonate.

Having briefly summarized the invention, the invention will now be described in detail by reference to the following specification and non-limiting examples. Unless otherwise specified, all percentages are by weight and all temperatures are in degrees Celsius.

DETAILED DESCRIPTION OF THE INVENTION

Therapeutic suspensions of LE for ophthalmic or otolaryngological uses are made by aseptic preparation. Purity levels of all materials employed in the suspensions of the invention exceed 98%. The suspensions of the invention are prepared by thoroughly mixing the soft steroid (component (A)), aminoglycoside (component (B)), suspending agent (component (C)), and surface active agent (component (D)). Optionally, tonicity agents (component (E)) and preservatives (component (F)) may be included.

Steroids of component (A), preferably soft steroids, most preferably LE, can be employed. Also other steroids such as beclomethasone, betamethasone, fluocinolone, fluorometholone, exednisolone, may be employed. The suspensions of component (A) of the invention have a particle size of about 0.1-30 μ, preferably about 1-20 μ, most preferably about 2-10 microns in mean diameter. LE in this size range is commercially available from suppliers such as the Sipsy Co., (Avrille, France).

The aminoglycoside component (B) is pharmaceutical grade. Aminoglycosides are a well-characterized family of antimicrobial agents and include, for example, gentamicin, neomycin paromomycin, kanamycin, tobramycin, netilmicin and amikacin. Tobramycin of this grade is commercially available from suppliers such as the Biogal Pharmaceutical Works (Debrecen, Hungary). Component (B) is preferably present in an amount that is effective to stabilize the pH of the composition relative to the pH of a similar composition without Component (B). Therefore the amount of Component (B) may vary depending upon the individual composition. Determining a pH stabilizing amount of an aminoglycoside for a particular composition can be readily achieved through routine experimentation and is within the purview of one skilled in the art.

The nonionic polymer of component (C) can be any nonionic water-soluble polymer. Typical compounds such as PVP, PVA, HPMC or dextran can be used at a concentration of about 0.01-2%, and preferably between about 0.4 to 1.5%, and more preferably between 0.4 to 1%. Viscosity increased above that of simple aqueous solutions may be desirable to increase ocular absorption of the active compound, to decrease variability in dispensing the formulation, to decrease physical separation of components of a suspension or emulsion of the formulation and/or to otherwise improve the ophthalmic formulation. Such viscosity builder agents include as examples polyvinyl alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose or other agents known to those skilled in the art. Povidone is preferably used as a suspending agent in the finished product and the water-soluble grades are routinely used in pharmaceuticals as a viscosity enhancing agent. The viscosity of aqueous solutions of the water-soluble grades of povidone depends on the average molecular weight. A subtle change in the grade and concentration of the suspending agent can yield the desired characteristics. Povidone comes in a variety of grades, of which some are water soluble. Povidone K-90 is the highest molecular weight water-soluble viscosity grade Povidone. This material is listed as Povidone, USP 90,000. The high molecular grade povidone dissolves much more slowly than the lower molecular weight grade.

Component (D) is a surface-active agent that is acceptable for ophthalmic or otolaryngological uses. Preferably, this surfactant is non-ionic. Useful surface active agents include but are not limited to polysorbate 80, tyloxapol, TWEEN 80 (ICI America Inc., Wilmington, Del.), PLURONIC F-68 (from BASF, Ludwigshafen, Germany) and the poloxamer surfactants. These surfactants are nonionic alkaline oxide condensates of

an organic compound that contains hydroxyl groups. The concentration in which the surface active agent may be used is only limited by neutralization of the bactericidal effects on the accompanying preservatives, or by concentrations that may cause irritation. Preferably, the concentration of component (D) is about 0.05 to 1%, and more preferably 0.1 to 0.6% by weight based on the weight of the suspension. Compositions of the present invention having a molar ratio of (A):(C):(D) between about 1:20:1 and about 1:0.01:0.5 are entirely suitable.

The tonicity agents of component (E) can be nonionic diols, preferably glycerol, in sufficient amounts to achieve isotonicity. The nonionic tonicity agents can be present in an amount of about 2 to 2.8% by weight, and preferably about 2.2 to 2.6%.

The nonionic polymeric compounds of component (C), and the surface active agents of component (D) have good solubility in water, have sufficient number of hydroxyl groups to interact with the steroid, and have mild effects on the viscosity of the suspension. Final viscosity should not exceed 80-centipoise.

The suspensions of the invention also may include additional therapeutic drugs such as drugs for treating glaucoma, anti-inflammatory drugs, anti-cancer drugs, anti-fungal drugs and anti-viral drugs. Examples of anti-glaucoma drugs include but are not limited to timolol-base, betaxalol, athenolol, levobanolol, epinenephrin, dipivalyl, oxonolol, acetazilumide-base and methazalomide. Examples of anti-inflammatory drugs include but are not limited to non-steroids such as piroxicam, indomethacin, naproxen, phenylbutazone, ibuprofen and diclofenac.

Health regulations in various countries generally require that ophthalmic preparations shall include a preservative. Many well known preservatives that have been used in ophthalmic preparations of the prior art, however, cannot be used in the

preparations of the invention, since those preservatives may no longer be considered safe for ocular use, or may interact with the surfactant employed in the suspension to form a complex that reduces the bactericidal activity of the preservative.

The preservatives of component (F) employed in the suspensions of the invention therefore are chosen to not interact with the surface active agent to an extent that the preservatives are prevented from protecting the suspension from microbiological contamination. In a preferred embodiment benzalkonium chloride may be employed as a safe preservative, most preferably benzalkonium chloride with EDTA. Other possible preservatives include but are not limited to benzyl alcohol, methyl parabens, propyl parabens, thimerosal, chlorbutanol and benzethonium chlorides. Typically such preservatives are employed at a level of from 0.001% to 1.0% by weight. Preferably, a preservative (or combination of preservatives) that will impart standard antimicrobial activity to the suspension and protect against oxidation of components (A)-(E) is employed.

In forming compositions for topical administration, the mixtures are preferably formulated as 0.01 to 2.0 percent by weight solutions in water at a pH of 4.5 to 8.0 (figures relate to combined presence of loteprednol etabonate and tobramycin). While the precise regimen is left to the discretion of the clinician, it is recommended that the resulting solution be topically applied by placing one drop in each eye two times a day.

A bioavailability study of LE-tobramycin vs. LOTEMAX loteprednol etabonate composition demonstrated that in the intend to treat population bioequivalence was met at both the 40 and 60 minute sampling periods. Thus, the inclusion of tobramycin does not alter the ocular bioavailability of loteprednol etabonate. A microbial kill rate study was undertaken to demonstrate antimicrobial equivalence between loteprednol etabonate

and tobramycin ophthalmic suspension, 0.5%/0.3% and tobramycin ophthalmic solution, USP 0.3%. The methods employed were based on USP anti-microbial effectiveness procedures for preparation of inoculum and challenge concentration of test organisms. The anti-microbial activity of both products was demonstrated against 22 organisms. The *in vitro* study demonstrated that tobramycin has equivalent anti-microbial activity as a single agent and when in combination with loteprednol etabonate.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments therefore are to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever. In the following examples, all temperatures are set forth in degrees Celsius; unless otherwise indicated, all parts and percentages are by weight.

EXAMPLES

A study was undertaken to compare a standard LE-tobramycin composition having different concentrations of Povidone and different types of Povidone. The example compositions also contained standard pharmaceutical components. Examples III and VI were used as controls (no tobramycin) to observe the effect of tobramycin on the pH of the composition. The materials were mixed with purified water and held at a temperature of 28 °C to represent room temperature stability and 40 °C to represent accelerated stability. The results are given in the tables below.

STABILITY OF LE-TOBRAMYCIN MATRIX (with different viscosity)
28 °C

	Time (month)	Tobra. (mg/ml)	LE (mg/ml)	pH
I	0	3.18	4.976	6.49
0.6%	1	3.076	--	6.32
PVP-C30	2	3.062	4.947	6.28
	3	3.113	5.484	6.21
	6	3.003	5.155	6.17
II	0	3.165	5.241	6.47
1.5%	1	3.04	--	6.3
PVP-C30	2	2.995	5.08	6.19
	3	3.04	5.32	6.14
	6	3.008	5.514	6.087
III	0	--	5.576	5.98
1.5%	1	--	--	5.54
PVP-C30	2	--	5.411	5.06
Control	3	--	5.706	5.02
	6	--	5.134	4.8
IV	0	3.206	5.296	6.71
1.5%	1	3.082	5.156	6.57
PVP-K90	2	3.122	5.29	6.49
	3	3.21	5.306	6.47
	6	3.146	5.358	6.39
V	0	2.802	4.32	6.61
0.5%	1	2.754	4.24	6.48
PVP-K90	2	2.596	4.28	6.38
	3	2.811	4.336	6.34
	6	2.806	4.365	6.32
VI	0	--	5.426	6.61
1.5%	1	--	5.638	5.033
PVP-K90	2	--	5.67	4.71
Control	3	--	5.67	4.72
	6	--	5.727	4.43

STABILITY OF LE-TOBRAMYCIN MATRIX (with different viscosity)

40 °C

	Time (month)	Tobra. (mg/ml)	LE (mg/ml)	pH
I	0	3.18	4.976	6.49
0.6%	1	3.15	--	6.23
PVP-C30	2	2.957	5.008	6.06
	3	3.036	5.067	5.95
	6			
II	0	3.165	5.241	6.47
1.5%	1	3.019	--	6.21
PVP-C30	2	2.91	5.16	5.89
	3	2.95	5.37	5.89
	6			
III	0	--	5.576	5.98
1.5%	1	--	--	4.73
PVP-C30	2	--	5.411	4.33
Control	3	--	5.473	4.11
	6	--		
IV	0	3.206	5.296	6.71
1.5%	1	2.94	5.336	6.47
PVP-K90	2	2.84	5.209	6.13
	3	3.17	5.17	6.25
	6	3.212	5.178	6.097
V	0	2.802	4.32	6.61
0.5%	1	2.588	4.284	6.38
PVP-K90	2	2.64	4.21	6.21
	3	2.82	4.2	6.14
	6	2.767	4.267	6.04
VI	0	--	5.426	6.61
1.5%	1	--	5.614	4.62
PVP-K90	2	--	5.91	3.93
Control	3	--	5.85	3.83
	6	--	5.572	3.53

The above data represents the results of pH stability testing of various compositions having differing viscosity. PVP-C30 is Povidone having a molecular

weight of around 30,000 and PVP-K90 is Povidone having a molecular weight of around 90,000. Both were obtained from the GAF Corporation, USA. In general a pH between 4.5 and 7.0 is considered acceptable for pharmaceutical ophthalmologic use of these compositions. The data demonstrates that compositions of the present invention having tobramycin display a more gradual decrease in pH over time and less of a total change in pH over time as compared to similar compositions which do not contain tobramycin.

The following example is a representative pharmaceutical composition of the invention for topical use where indicated against inflammation and infection.

EXAMPLE 1

Ingredients (per mL)

Loteprednol etabonate 0.5% (5 mg)
Glycerin 2.5%
Povidone, K-90 0.6%
Tobramycin 0.3% (3 mg)
Benzalkonium Chloride 0.01%
Tyloxapol 0.05%
Edentate disodium 0.01%
Purified water (QS to 100%)
Sulfuric acid or sodium hydroxide (to adjust pH)

What is claimed is:

1. A composition for ophthalmic or otolaryngological anti-inflammatory use comprising:

(A) loteprednol etabonate having a particle size of 0.1 to 30 microns in diameter in an amount of about 0.2 to 2% by weight;

(B) tobramycin in an amount effective to stabilize the pH of the composition relative to the pH of a similar composition without the tobramycin;

(C) a nonionic polymer in an aqueous medium; and

(D) a nonionic surface active agent in an amount sufficient to retain the corticosteroid in suspension, wherein the molar ratio of (A):(C):(D) is between about 1:20:1 and about 1:0.01:0.5.

2. The composition of claim 1 further comprising:

(E) a nonionic tonicity agent in an amount sufficient to achieve isotonicity.

3. The composition of claim 1 wherein the loteprednol etabonate is present in an amount of about 0.5 to 1% by weight.

4. The composition of claim 1 wherein the loteprednol etabonate has a particle size less than about fifteen microns.

5. The composition of claim 4 wherein the tobramycin is present in an effective anti-infection amount.

6. The composition of claim 1 further including a preservative for preventing microbial formation in said composition and in an amount of about 0.01 to 0.025% by weight.

7. The composition of claim 6 wherein said preservative is benzalkonium chloride.

8. The composition of claim 7 further comprising disodium edentate.

9. The composition of claim 1 wherein said nonionic polymer is selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, or dextran and is present in an amount of about 0.2 to 2% by weight and wherein the nonionic surfactant is present in an amount of about 0.05 to 1% by weight.

10. The composition of claim 1 wherein said nonionic polymer is polyvinylpyrrolidone and is present in an amount of about 0.4 to 1% by weight.

11. The composition of claim 1 wherein said nonionic surface active agent is tyloxapol and is present in an amount of about 0.1 to 0.6% by weight.

12. The composition of claim 1 further comprising an additional therapeutic drug in admixture with said soft steroid and tobramycin, wherein said additional therapeutic drug is selected from the group consisting of betaxalol, athenolol, levobanolol, epinenephrin, dipivalyl, oxonolol, acetazilumide-base, methazalomide, piroxicam, indomethacin, naproxen, phenylbutazone, ibuprofen, and diclofenac-acid.

13. A composition for ophthalmic or otolaryngological anti-inflammatory and anti-infection use comprising a nonionic polymer in an aqueous medium, a nonionic tonicity agent in an amount effective to achieve isotonicity, and a nonionic surface active agent in an amount sufficient to retain the polymer and tonicity agent in the aqueous medium, tobramycin; and further comprising a soft steroid having a particle size of 0.1 to 30 microns in diameter in an amount of about 0.2 to 2% by weight, wherein the composition is bioequivalent to a similar loteprednol etabonate formulation that does not contain tobramycin.

14. The composition of claim 13 wherein said nonionic tonicity agent is a nonionic diol and is present in an amount of about 2 to 2.8% by weight.

15. The composition of claim 13 wherein the nonionic polymer is present in an amount of about 0.2 to 2% by weight; the nonionic tonicity agent is present in an amount of about 2 to 2.8% by weight; and the nonionic surface active agent is present in an amount of about 0.05 to 1% by weight.

16. The composition of claim 13 further comprising a preservative of benzalkonium chloride, disodium edentate, and mixtures thereof in an amount of about 0.01 to 0.025% by weight.

17. The composition of claim 13 wherein the nonionic polymer is polyvinyl pyrrolidone and is present in an amount of about 0.4 to 1% by weight, the nonionic

tonicity agent is mannitol or a diol and is present in an amount of about 2 to 2.8% by weight, and the nonionic surface active agent is tyloxapol and is present in an amount of about 0.1 to 0.6% by weight.

18. The composition of claim 2 wherein the loteprednol etabonate is present in an amount of between about 0.01 and 1% by weight.

19. The composition of claim 2 wherein the loteprednol etabonate and is present in an amount of between about 0.05 and about 0.5% by weight.

20. The composition of claim 2 wherein said nonionic polymer is a water soluble polymer selected from the group consisting of polyvinylpyrrolidone, polyvinyl alcohol, dextran and cyclodextrin.

21. The composition of claim 2 wherein the nonionic polymer is present in an amount of about 0.2 to 2% by weight.

22. The composition of claim 20, wherein said nonionic polymer is polyvinylpyrrolidone and is present in an amount of between about 0.3 to about 1.75% by weight.

23. The composition of claim 2 wherein said nonionic surface active agent is tyloxapol and is present in an amount of about 0.05 to about 1% by weight.

24. The composition of claim 2, wherein said nonionic surface active agent is a polyoxyethylene sorbitan mono-oleate ester.

25. The composition of claim 22 wherein the nonionic tonicity agent is present in an amount of between about 1 to about 7% by weight.

26. The composition of claim 25 wherein the nonionic tonicity agent is a nonionic polyol and is present in an amount of between about 1.5 to about 4% by weight.

27. The composition of claim 26 wherein the nonionic tonicity agent is glycerol or mannitol.

28. The composition of claim 2 further including a preservative for preventing microbial formation in said composition and is present in an amount of between about 0.0001 to about 0.025% by weight.

29. The composition of claim 28 wherein said preservative is selected from the group consisting of benzalkonium chloride, disodium edetate and mixtures thereof.

30. The composition of claim 2 further comprising an additional therapeutic drug in admixture with said soft steroid and tobramycin, wherein said additional therapeutic drug is selected from the group consisting of betaxolol, atenolol, levobunolol, epinephrin, dipivalyl, oxonolol, acetazolamide-base, methazolamide, piroxicam, indomethacin, naproxen, phenylbutazone, ibuprofen, and diclofenac.

31. The composition of claim 2 wherein the nonionic polymer is present in an amount of between about 0.2 to about 2% by weight; the nonionic tonicity agent is present in an amount of between about 1 to about 7% by weight; and the nonionic surface active agent is present in an amount of between about 0.05 to about 1% by weight.

32. The composition of claim 31 further comprising a preservative for preventing microbial formation in said composition and is present in an amount of about 0.0001 to 0.025% by weight.

33. A method for treating ophthalmic or otolaryngological inflammation and infection which comprises applying to inflamed tissue a composition comprising:
(A) loteprednol etabonate in an amount of 0.01 to about 2% by weight and having a particle size of about 0.1 to 30 microns in diameter to substantially prevent discomfort upon use of the composition for said ophthalmic or otolaryngological anti-inflammatory treatment;
(B) an amount of tobramycin effective to stabilize the pH of the composition relative to the pH of a similar composition without the tobramycin;
(C) a nonionic polymer in an aqueous medium; and
(D) a nonionic surface active agent in an amount sufficient to retain the soft steroid in suspension;
wherein said composition is applied in an amount effective to treat said inflammation and infection.

34. The method of claim 33 wherein the nonionic polymer is present in an amount of between about 0.2 to about 2% by weight, the non-ionic tonicity agent is present in an amount of between about 1 to about 7% by weight, and the nonionic surface active agent is present in an amount of between about 0.05 to about 1% by weight, and wherein the molar ratio of (A):(C):(D) is about 1:0.01:0.05 to about 1:20:1.

INTERNATIONAL SEARCH REPORT

PCT/US2004/035562

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/10 A61K31/56 A61K31/7036

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, PAJ, BIOSIS, MEDLINE, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/11669 A (PHARMOS CORPORATION; GUY, YAACOV, J; FRIEDMAN, DORON) 4 May 1995 (1995-05-04) page 6, line 1 - line 7 page 8, line 20 - line 23 page 9, line 16 - line 19 claims 1-21	1-34
E	WO 2005/000317 A (BODOR, NICHOLAS, S) 6 January 2005 (2005-01-06) page 36, line 21 - line 27 example 1	1
A	US 2002/098154 A1 (DYER GORDON WAYNE) 25 July 2002 (2002-07-25) claims 1,4	1-34

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
22 March 2005	06/04/2005

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Sindel, U

INTERNATIONAL SEARCH REPORT

Information on patent family members

PCT/US2004/035562

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9511669 A	04-05-1995	US 5540930 A	30-07-1996
		AT 217523 T	15-06-2002
		AU 697617 B2	15-10-1998
		AU 7983594 A	22-05-1995
		BR 9407958 A	26-11-1996
		CA 2174550 A1	04-05-1995
		DE 69430635 D1	20-06-2002
		DE 69430635 T2	02-01-2003
		DK 730443 T3	09-09-2002
		EP 0730443 A1	11-09-1996
		ES 2179851 T3	01-02-2003
		HU 74882 A2	28-02-1997
		IL 111402 A	06-12-2000
		JP 9504294 T	28-04-1997
		JP 3570720 B2	29-09-2004
		NZ 275749 A	26-02-1998
		PT 730443 T	29-11-2002
		SG 48768 A1	18-05-1998
		WO 9511669 A1	04-05-1995
		US 5747061 A	05-05-1998
WO 2005000317 A	06-01-2005	US 2005026892 A1	03-02-2005
		WO 2005000317 A1	06-01-2005
US 2002098154 A1	25-07-2002	NONE	